Jasper Therapeutics increases inducement equity plan to 5.5M shares; charter amended for officer exculpation

Jasper Therapeutics, Inc.

Compensation Committee approved amendment to 2022 Inducement Plan, increasing shares from 3M to 5.5M (2.5M new shares).
Amendment adopted without stockholder approval under Nasdaq Rule 5635(c)(4) for inducement awards to new employees.
At June 7 Annual Meeting, stockholders elected Anna French and Judith Shizuru as Class II directors.
Stockholders ratified PricewaterhouseCoopers as independent auditor for FY2023.
Stockholders approved amendment to Certificate of Incorporation for officer exculpation under new Delaware law.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Jasper Therapeutics, Inc.: Amended certificate of incorporation to add officer exculpation provisions under new Delaware law (effective 2023-06-08).

Change: charter amendment
Effective: 2023-06-08

Exact text from the filing

On June 7, 2023, the Company held its 2023 Annual Meeting of Stockholders (the “Meeting”). At the Meeting, the Company’s stockholders approved an amendment to the Company’s Second Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) to reflect new Delaware law provisions regarding officer exculpation (the “Amendment”).

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Jasper Therapeutics, Inc. shareholders approved To approve an amendment to the Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation. at the 2023-06-07 meeting.

Proposal: charter amendment
Outcome: passed
Meeting: 2023-06-07

Exact text from the filing

Proposal No. 3 : To approve an amendment to the Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation. Votes For Votes Against Abstentions Broker Non-Votes 73,923,961 7,116,389 23,804 10,839,662

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Jasper Therapeutics, Inc. shareholders approved To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2023. at the 2023-06-07 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-06-07

Exact text from the filing

Proposal No. 2: To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2023. Votes For Votes Against Abstentions 91,856,308 37,101 10,407

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Jasper Therapeutics, Inc. shareholders approved To elect two Class II directors to serve until the 2026 annual meeting of stockholders and until their successors are duly elected and qualified. at the 2023-06-07 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-06-07

Exact text from the filing

Director Nominee Votes For Votes Withheld Broker Non-Votes Anna French, D. Phil. 69,570,975 11,493,179 10,839,662 Judith Shizuru, M.D., Ph.D. 72,204,829 8,859,325 10,839,662

View on SEC.gov

42 governance changes filed in the last 30 days. Browse all governance changes →

Jasper Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-047446

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.